<DOC>
	<DOCNO>NCT02722018</DOCNO>
	<brief_summary>This phase 1 , randomize , open-label , single center , crossover study investigate effect formulation food pharmacokinetics GDC-0810 female healthy participant non-childbearing potential . This study divide three part . Participants part randomize one three treatment sequence . Part 1 study 4 period investigate effect formulation pharmacokinetics ( PK ) GDC-0810 administer low-fat food . Each participant part receive single dose GDC-0810 dose level A follow consumption low fat meal ( 30 minute start meal ) treatment period . Part 2 optional Phase I study 3 period investigate effect formulation PK GDC-0810 administer low-fat food healthy female participant non-childbearing potential . Part 3 study three period compare PK Phase III prototype tablet formulation select Parts 1 2 study Phase II tablet formulation ( administer 30 minute start low fat meal ) dose level B investigate PK Phase III prototype formulation administer fasted state .</brief_summary>
	<brief_title>Study Investigate Effect Formulation Food Pharmacokinetics GDC-0810</brief_title>
	<detailed_description />
	<criteria>Female healthy participant 40 70 year age , inclusive Female participant nonchildbearing potential include nonpregnant , nonlactating , either postmenopausal surgically sterile least 45 day post procedure Body mass index ( BMI ) range 18.0 32.0 kilogram per meter square ( kg/m^2 ) , inclusive In good health , determine clinically significant finding medical history , physical examination , 12lead electrocardiogram ( ECG ) , vital sign , clinical laboratory evaluation Receive explanation mandatory pharmacogenomics ( PgX ) component study Any history endometrial polyp , endometrial cancer , atypical endometrial hyperplasia , endometrial disorder unless subject undergone total hysterectomy evidence active disease Significant history clinical manifestation significant metabolic , allergic , dermatological , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , neurological , psychiatric disorder History thrombophilic condition , inflammatory bowel disease , active bowel inflammation , chronic diarrhea , short bowel syndrome , upper gastrointestinal ( GI ) surgery include gastric resection Any history venous thrombosis ( include pulmonary embolism [ PE ] ) Participation investigational study drug trial receipt investigational study drug occur within 90 day prior Checkin ( Day 1 ) Period 1 Use systemic hormone replacement therapy within 1 year prior Checkin ( Day 1 ) History use tamoxifen , aromatase inhibitor , endocrine agent treatment breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>